266 related articles for article (PubMed ID: 27208638)
1. Yellow fever vaccination status and safety in hemodialysis patients.
Facincani T; Guimarães MN; De Sousa Dos Santos S
Int J Infect Dis; 2016 Jul; 48():91-5. PubMed ID: 27208638
[TBL] [Abstract][Full Text] [Related]
2. Review of the risks and benefits of yellow fever vaccination including some new analyses.
Monath TP
Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
[TBL] [Abstract][Full Text] [Related]
3. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
[TBL] [Abstract][Full Text] [Related]
4. Adverse event reports following yellow fever vaccination, 2007-13.
Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
[TBL] [Abstract][Full Text] [Related]
5. Adverse event reports following yellow fever vaccination.
Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
[TBL] [Abstract][Full Text] [Related]
6. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Staples JE; Gershman M; Fischer M;
MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
[TBL] [Abstract][Full Text] [Related]
7. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.
Miyaji KT; Luiz AM; Lara AN; do Socorro Souza Chaves T; Piorelli Rde O; Lopes MH; Sartori AM
Hum Vaccin Immunother; 2013 Feb; 9(2):277-82. PubMed ID: 23291944
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
[TBL] [Abstract][Full Text] [Related]
9. Safety of the yellow Fever vaccine: a retrospective study.
Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
[TBL] [Abstract][Full Text] [Related]
10. Yellow fever vaccine for patients with HIV infection.
Barte H; Horvath TH; Rutherford GW
Cochrane Database Syst Rev; 2014 Jan; (1):CD010929. PubMed ID: 24453061
[TBL] [Abstract][Full Text] [Related]
11. Adverse events following yellow fever vaccination in immunocompromised persons.
Lara AN; Miyaji KT; Ibrahim KY; Lopes MH; Sartori AMC
Rev Inst Med Trop Sao Paulo; 2021; 63():e13. PubMed ID: 33656136
[TBL] [Abstract][Full Text] [Related]
12. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
Rafferty E; Duclos P; Yactayo S; Schuster M
Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
[TBL] [Abstract][Full Text] [Related]
13. [Yellow fever vaccination in non-immunocompetent patients].
Bruyand M; Receveur MC; Pistone T; Verdière CH; Thiebaut R; Malvy D
Med Mal Infect; 2008 Oct; 38(10):524-32. PubMed ID: 18715730
[TBL] [Abstract][Full Text] [Related]
14. Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA.
Rojas A; Hachey W; Kaur G; Korejwo J; Muhammad R
J Travel Med; 2023 Nov; 30(7):. PubMed ID: 37000007
[TBL] [Abstract][Full Text] [Related]
15. Yellow fever vaccine: past, present and future.
Roukens AH; Visser LG
Expert Opin Biol Ther; 2008 Nov; 8(11):1787-95. PubMed ID: 18847312
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
[TBL] [Abstract][Full Text] [Related]
17. Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
Ledlie S; Ricci C; Pan C; Rojas A; Khromava A; Li L
Vaccine; 2022 Jan; 40(5):742-751. PubMed ID: 34996642
[TBL] [Abstract][Full Text] [Related]
18. Duration of post-vaccination humoral immunity against yellow fever in children.
de Noronha TG; de Lourdes de Sousa Maia M; Geraldo Leite Ribeiro J; Campos Lemos JA; Maria Barbosa de Lima S; Martins-Filho OA; Campi-Azevedo AC; da Silva Freire M; de Menezes Martins R; Bastos Camacho LA;
Vaccine; 2019 Nov; 37(48):7147-7154. PubMed ID: 31590934
[TBL] [Abstract][Full Text] [Related]
19. Transfusion-related transmission of yellow fever vaccine virus--California, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Jan; 59(2):34-7. PubMed ID: 20094025
[TBL] [Abstract][Full Text] [Related]
20. Yellow fever: the recurring plague.
Tomori O
Crit Rev Clin Lab Sci; 2004; 41(4):391-427. PubMed ID: 15487593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
